[go: up one dir, main page]

LUC00257I2 - - Google Patents

Download PDF

Info

Publication number
LUC00257I2
LUC00257I2 LU00257C LUC00257C LUC00257I2 LU C00257 I2 LUC00257 I2 LU C00257I2 LU 00257 C LU00257 C LU 00257C LU C00257 C LUC00257 C LU C00257C LU C00257 I2 LUC00257 I2 LU C00257I2
Authority
LU
Luxembourg
Application number
LU00257C
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00257(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of LUC00257I2 publication Critical patent/LUC00257I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU00257C 2012-11-21 2022-05-06 LUC00257I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261728912P 2012-11-21 2012-11-21
US201361782550P 2013-03-14 2013-03-14
US201361809541P 2013-04-08 2013-04-08
US201361864717P 2013-08-12 2013-08-12
US201361892797P 2013-10-18 2013-10-18
PCT/US2013/071288 WO2014081954A1 (fr) 2012-11-21 2013-11-21 Anticorps egfr/c-met bispécifiques

Publications (1)

Publication Number Publication Date
LUC00257I2 true LUC00257I2 (fr) 2025-04-25

Family

ID=50728148

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00257C LUC00257I2 (fr) 2012-11-21 2022-05-06

Country Status (36)

Country Link
US (3) US9593164B2 (fr)
EP (4) EP2922872B1 (fr)
JP (6) JP6423357B2 (fr)
KR (4) KR20250054125A (fr)
CN (2) CN113201073A (fr)
AU (4) AU2013347962B2 (fr)
BR (1) BR112015011717B1 (fr)
CA (2) CA2893505C (fr)
CL (1) CL2015001356A1 (fr)
CY (2) CY1121270T1 (fr)
DK (2) DK3447069T3 (fr)
EA (1) EA031184B1 (fr)
ES (3) ES2831374T3 (fr)
FI (1) FIC20220016I1 (fr)
FR (1) FR22C1018I2 (fr)
HR (2) HRP20182128T1 (fr)
HU (3) HUE041499T2 (fr)
IL (1) IL238796B (fr)
LT (3) LT3447069T (fr)
LU (1) LUC00257I2 (fr)
MX (1) MX361088B (fr)
MY (1) MY172867A (fr)
NI (1) NI201500069A (fr)
NL (1) NL301173I2 (fr)
NO (1) NO2022012I1 (fr)
NZ (1) NZ708352A (fr)
PE (1) PE20151181A1 (fr)
PH (1) PH12015501118B1 (fr)
PL (1) PL2922872T3 (fr)
PT (2) PT2922872T (fr)
RS (2) RS61057B1 (fr)
SG (1) SG11201503938VA (fr)
SI (2) SI2922872T1 (fr)
SM (2) SMT202000619T1 (fr)
UA (1) UA117121C2 (fr)
WO (1) WO2014081954A1 (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010282A (es) 2007-03-29 2009-10-12 Genmab As Anticuerpos biespecificos y metodos para su produccion.
KR101791430B1 (ko) * 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
CA3254586A1 (en) * 2010-03-10 2025-11-29 Genmab A/S Monoclonal anti bodi es against c-met
ES2989108T3 (es) 2010-04-20 2024-11-25 Genmab As Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas
CA2800785C (fr) 2010-05-27 2019-09-24 Genmab A/S Anticorps monoclonaux contre her2
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR20250054125A (ko) * 2012-11-21 2025-04-22 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
KR102478402B1 (ko) 2013-10-14 2022-12-15 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
WO2015119122A1 (fr) 2014-02-04 2015-08-13 アステラス製薬株式会社 Composition médicinale comprenant un composé de carboxamide hétérocyclique diamino en tant qu'agent actif
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
US10507210B2 (en) * 2014-12-03 2019-12-17 Auckland Uniservices Limited Kinase inhibitor prodrug for the treatment of cancer
WO2016100233A1 (fr) 2014-12-15 2016-06-23 The Regents Of The University Of California Molécules cytotoxiques réagissant à des ligands intracellulaires pour la destruction sélective médiée par les lymphocytes t
WO2016100232A1 (fr) 2014-12-15 2016-06-23 The Regents Of The University Of California Récepteur d'antigène chimère de type porte ou bispécifique sensible à cd19 et à cd20
WO2016097300A1 (fr) 2014-12-19 2016-06-23 Genmab A/S Protéines hétérodimères bispécifiques de rongeurs
SMT202400477T1 (it) * 2014-12-22 2025-01-14 Systimmune Inc Anticorpi tetravalenti bispecifici e loro procedimenti di fabbricazione e d'uso
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016182513A1 (fr) * 2015-05-13 2016-11-17 Singapore Health Services Pte Ltd Établissement de profils du carcinome hépatocellulaire et applications correspondantes
HRP20210483T1 (hr) 2015-10-23 2021-07-09 Merus N.V. Vezujuće molekule koje inhibiraju rast raka
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
AU2016349152A1 (en) * 2015-11-03 2018-06-14 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
WO2017136820A2 (fr) * 2016-02-06 2017-08-10 Epimab Biotherapeutics, Inc. Technologie fit-immunoglobuline et ses utilisations
MX383920B (es) 2016-05-26 2025-03-14 Recurium Ip Holdings Llc Compuestos inhibidores de egfr.
KR101985299B1 (ko) * 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
SG11201811062XA (en) * 2016-06-21 2019-01-30 Janssen Biotech Inc Cysteine engineered fibronectin type iii domain binding molecules
US11701384B2 (en) 2016-09-02 2023-07-18 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN110177571B (zh) 2016-11-18 2024-05-24 加利福尼亚大学董事会 工程化抗体及其用途
EP3554535A4 (fr) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii se liant à pd-l1
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech, Inc. domínios do tipo iii da fibronectina de ligação a cd8a
EP3554561B1 (fr) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Domaines de fibronectine de type iii à liaison au cd137
TWI723247B (zh) * 2017-02-06 2021-04-01 中央研究院 重組蛋白及其用途
KR20260006707A (ko) 2017-03-31 2026-01-13 메뤼스 엔.페. NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB2 및 ErbB3 결합 이중특이적 항체
AU2018271157C1 (en) 2017-05-17 2021-11-18 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
US11479612B2 (en) * 2017-05-30 2022-10-25 Chong Kun Dang Pharmaceutical Corp. Anti-c-Met antibody and use thereof
WO2018221969A1 (fr) * 2017-05-30 2018-12-06 Chong Kun Dang Pharmaceutical Corp. Nouvel anticorps anti-c-met et son utilisation
DK3665198T3 (da) 2017-08-09 2025-04-28 Merus Nv Antistoffer, der binder egfr og cmet
EP3672611A4 (fr) * 2017-08-25 2021-07-14 Janssen Biotech, Inc. DOMAINES DE TYPE III DE FIBRONECTINE LIANT FCyRII, LEURS CONJUGUÉS ET MOLÉCULES MULTISPÉCIFIQUES LES COMPRENANT
WO2019114793A1 (fr) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 Anticorps egfr, son procédé de préparation et son application
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3101272A1 (fr) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Agents de liaison psma et utilisations correspondantes
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
CA3111980A1 (fr) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Polytherapies
KR102871791B1 (ko) * 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
JP7539902B2 (ja) * 2018-10-22 2024-08-26 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
TWI874341B (zh) * 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
PH12021552030A1 (en) 2019-02-26 2022-08-15 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
EP3956022A1 (fr) 2019-04-19 2022-02-23 Janssen Biotech, Inc. Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
SG11202112412QA (en) * 2019-05-14 2021-12-30 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
EP4045061A4 (fr) 2019-10-14 2024-04-17 ARO Biotherapeutics Company Domaines de type iii de fibronectine de liaison à cd137
JOP20220184A1 (ar) * 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CA3192922A1 (fr) * 2020-08-25 2022-03-03 Janssen Biotech, Inc. Traitement du cancer du poumon non a petites cellules presentant des mutations egfr
AR123340A1 (es) * 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
JP2023542296A (ja) * 2020-09-14 2023-10-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｆｇｆｒ阻害剤の併用療法
KR20230137393A (ko) 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
JP2024509920A (ja) * 2021-03-09 2024-03-05 ヤンセン バイオテツク，インコーポレーテツド Ｅｇｆｒ活性化変異を欠くがんの治療
CA3215367A1 (fr) 2021-04-14 2022-10-20 Swapnil Kulkarni Conjugues domaine fn3-arnsi et leurs utilisations
EP4323409A4 (fr) 2021-04-14 2025-04-16 ARO Biotherapeutics Company Domaines fibronectine de type iii de liaison à cd71
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
TW202309094A (zh) * 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
MX2024000501A (es) * 2021-07-14 2024-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a hgfr y egfr, y su uso farmaceutico.
US12441816B2 (en) 2021-09-21 2025-10-14 Qilu Puget Sound Biotherapeutics Corporation Heterodimeric Fc for making fusion proteins and bispecific antibodies
JP2024538148A (ja) * 2021-10-18 2024-10-18 タボテック バイオセラピューティクス（ホンコン）リミティド 抗ＥＧＦＲ抗体、抗ｃＭＥＴ抗体、抗ＶＥＧＦ抗体、多重特異性抗体及びそれらの使用
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
KR20240144944A (ko) 2022-01-28 2024-10-04 온퀄리티 파마슈티컬스 차이나 리미티드 항종양제와 관련된 질병 또는 증상을 예방하거나 치료하는 방법
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
EP4484429A1 (fr) 2022-02-21 2025-01-01 OnQuality Pharmaceuticals China Ltd. Composé et son utilisation
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法
US20250382373A1 (en) * 2022-06-29 2025-12-18 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/met antibodies and uses thereof
CA3260989A1 (fr) 2022-06-30 2024-01-04 Janssen Biotech, Inc. Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou œsophagien
EP4624493A1 (fr) * 2022-11-24 2025-10-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Composition pharmaceutique comprenant un anticorps bispécifique se liant spécifiquement à hgfr et à egfr
EP4680639A1 (fr) 2023-03-13 2026-01-21 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-egfr/c-met bispécifiques et des anticorps anti-pd-1
WO2024193449A1 (fr) * 2023-03-17 2024-09-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anticorps anti-her3 et anti-met et leurs utilisations
EP4454706A1 (fr) * 2023-04-24 2024-10-30 Universität Stuttgart Nouvelles protéines de liaison à l'egfr
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2024258870A2 (fr) 2023-06-12 2024-12-19 Amgen Inc. Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine
WO2025011471A1 (fr) * 2023-07-07 2025-01-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Protéine de liaison bispécifique à egfr/c-met et son utilisation
WO2025017409A1 (fr) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Schéma posologique pour thérapies comprenant des anticorps anti-egfr/c-met bispécifiques
WO2025025434A1 (fr) * 2023-08-02 2025-02-06 百泰生物药业有限公司 Anticorps bispécifique egfr/c-met et son utilisation
WO2025052273A1 (fr) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Méthodes pour traiter le cancer du poumon non à petites cellules
WO2025067492A1 (fr) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 Utilisation d'un anticorps bispécifique dans la préparation d'un médicament pour le traitement de cancers
WO2025079020A1 (fr) 2023-10-12 2025-04-17 Janssen Biotech, Inc. Traitement de première intention pour le cancer du poumon non à petites cellules avancé muté avec une insertion dans l'exon 20 de l'egfr
TW202527997A (zh) * 2023-11-15 2025-07-16 大陸商四川科倫博泰生物醫藥股份有限公司 靶向ｅｇｆｒ／ｃ—ｍｅｔ之抗體—藥物結合物以及其製備方法及用途
TW202532100A (zh) * 2023-12-22 2025-08-16 大陸商信達生物製藥（蘇州）有限公司 靶向b7h3和egfr的雙特異性抗體-藥物偶聯物及其應用
WO2025153988A1 (fr) 2024-01-16 2025-07-24 Janssen Biotech, Inc. Utilisation d'amivantamab pour traiter le cancer colorectal
WO2025158277A1 (fr) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Utilisation d'amivantamab pour traiter le cancer de la tête et du cou
WO2025191459A1 (fr) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Utilisation d'anticorps anti-egfr/c-met bispécifiques pour traiter des tumeurs solides
WO2025247330A1 (fr) * 2024-05-31 2025-12-04 江苏先声生物制药有限公司 Conjugué anticorps-médicament bispécifique anti-egfr × cmet et son utilisation
WO2026017120A1 (fr) * 2024-07-18 2026-01-22 信达生物制药(苏州)有限公司 Anticorps trispécifique anti-cdh17/egfr/cd16a et son utilisation

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1991003489A1 (fr) 1989-09-08 1991-03-21 The Johns Hopkins University Modifications structurelles du gene recepteur du facteur de croissance epidermique dans les gliomes humains
ATE168416T1 (de) 1989-10-05 1998-08-15 Optein Inc Zellfreie synthese und isolierung von genen und polypeptiden
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69233153T2 (de) 1991-03-06 2004-05-27 Merck Patent Gmbh Humanisierte monoklonale antikörper
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
PT1392359E (pt) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
CN100497389C (zh) * 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1283053A1 (fr) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de l'activité de HER3
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
DK1534830T3 (da) 2002-09-06 2011-02-14 Isogenica Ltd In vito-peptid-ekspressionsbibliotek
WO2004072117A2 (fr) 2003-02-13 2004-08-26 Pharmacia Corporation Anticorps contre c-met dans le traitement de cancers
DK1648998T3 (en) 2003-07-18 2015-01-05 Amgen Inc Specific binding agents for hepatocyte growth factor
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2569520C (fr) 2004-06-04 2023-03-14 Genentech, Inc. Mutations de kras destinees a identifier des tumeurs colorectales reagissant au cetuximab ou au panitumumab
ES2344793T3 (es) 2004-08-05 2010-09-07 Genentech, Inc. Antagonistas anti-cmet humanizados.
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
WO2006106905A1 (fr) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d’un ensemble
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2851091B1 (fr) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Procédés de traitement d'un cancer résistant à des agents thérapeutiques ERBB
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
US20110256142A1 (en) 2007-09-06 2011-10-20 Genmab A/S Novel methods and antibodies for treating cancer
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CA2710378A1 (fr) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Vecteurs de phages de synthese destines a la conception et a la generation d'une banque de phages proteines ou peptides non anticorps humains par fusion au pix du phage m13;
CA2710373A1 (fr) 2007-12-19 2009-07-09 Ping Tsui Conception et generation de banques d'exposition sur phage humain pix de novo au moyen d'une fusion vers pix ou pvii, vecteur, anticorps et procedes
KR20100135780A (ko) 2008-03-06 2010-12-27 제넨테크, 인크. Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
CL2009000843A1 (es) 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
EA022884B1 (ru) * 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА
EP2349328A1 (fr) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Méthodes de traitement du cancer
WO2010051274A2 (fr) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Compositions d'échafaudage à base de domaines de la fibronectine de type iii, procédés et utilisations
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
JP5612663B2 (ja) 2009-04-07 2014-10-22 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ＥｒｂＢ−１／抗ｃ−Ｍｅｔ抗体
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
NZ598929A (en) * 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
KR101791430B1 (ko) 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
CA3254586A1 (en) * 2010-03-10 2025-11-29 Genmab A/S Monoclonal anti bodi es against c-met
ES2989108T3 (es) * 2010-04-20 2024-11-25 Genmab As Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas
PT3103478T (pt) 2010-04-30 2019-07-10 Janssen Biotech Inc Composições, métodos e utilizações de domínios de fibronectinas estabilizadas
AU2010355523B2 (en) * 2010-06-15 2014-09-11 Alberto Bardelli MLK4 gene, a new diagnostic and prognostic marker in cancers
EP2621953B1 (fr) * 2010-09-30 2017-04-05 Ablynx N.V. Matières biologiques associées à c-met
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
IL296507A (en) * 2011-10-10 2022-11-01 Hope City Meditops and Meditop binding antibodies and their use
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR20250054125A (ko) * 2012-11-21 2025-04-22 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
UA117121C2 (uk) 2018-06-25
EA201590985A1 (ru) 2015-11-30
EP3447069A1 (fr) 2019-02-27
KR20150087365A (ko) 2015-07-29
MX361088B (es) 2018-11-26
US9580508B2 (en) 2017-02-28
NL301173I2 (nl) 2022-06-15
CN113201073A (zh) 2021-08-03
US20140255408A1 (en) 2014-09-11
SMT202000619T1 (it) 2021-01-05
JP2019048817A (ja) 2019-03-28
IL238796B (en) 2019-06-30
CA2893505A1 (fr) 2014-05-30
KR20220032654A (ko) 2022-03-15
US9695242B2 (en) 2017-07-04
AU2021202394B2 (en) 2024-03-07
ES2971536T3 (es) 2024-06-05
LT2922872T (lt) 2018-12-27
JP2021006561A (ja) 2021-01-21
JP2016505537A (ja) 2016-02-25
LTPA2022507I1 (fr) 2022-06-27
WO2014081954A1 (fr) 2014-05-30
AU2013347962B2 (en) 2018-10-25
HUS2200016I1 (hu) 2022-05-28
FR22C1018I1 (fr) 2022-06-17
EP3447069B1 (fr) 2020-09-23
JP2026015326A (ja) 2026-01-29
EP4420727A3 (fr) 2024-10-23
US9593164B2 (en) 2017-03-14
KR102373193B1 (ko) 2022-03-10
JP2024026236A (ja) 2024-02-28
RS58192B1 (sr) 2019-03-29
MY172867A (en) 2019-12-13
NO2022012I1 (no) 2022-05-06
US20170101475A1 (en) 2017-04-13
CY1123550T1 (el) 2022-03-24
JP7756699B2 (ja) 2025-10-20
MX2015006387A (es) 2015-12-03
KR20250054125A (ko) 2025-04-22
EP2922872A1 (fr) 2015-09-30
RS61057B1 (sr) 2020-12-31
ES2700231T3 (es) 2019-02-14
KR20240005211A (ko) 2024-01-11
AU2013347962A1 (en) 2015-05-28
LTC2922872I2 (fr) 2024-09-10
AU2021202394A1 (en) 2021-05-20
JP6423357B2 (ja) 2018-11-14
LT3447069T (lt) 2020-12-10
CN104955838B (zh) 2021-02-02
KR102795571B1 (ko) 2025-04-11
CA3182876A1 (fr) 2014-05-30
US20140141000A1 (en) 2014-05-22
EP3808767B1 (fr) 2023-12-06
CN104955838A (zh) 2015-09-30
NI201500069A (es) 2015-10-19
FIC20220016I1 (fi) 2022-05-31
EP2922872A4 (fr) 2016-07-06
EP2922872B1 (fr) 2018-10-10
HUE041499T2 (hu) 2019-05-28
DK2922872T3 (da) 2019-01-02
JP2022062155A (ja) 2022-04-19
HRP20201848T1 (hr) 2021-01-08
CL2015001356A1 (es) 2015-11-06
SI3447069T1 (sl) 2021-02-26
PH12015501118A1 (en) 2016-02-01
SG11201503938VA (en) 2015-06-29
BR112015011717B1 (pt) 2023-12-12
BR112015011717A2 (pt) 2017-08-15
AU2024203417A1 (en) 2024-06-13
SI2922872T1 (sl) 2019-01-31
FR22C1018I2 (fr) 2023-05-05
AU2019200441B2 (en) 2021-01-28
JP7397105B2 (ja) 2023-12-12
PL2922872T3 (pl) 2019-03-29
EP3808767C0 (fr) 2023-12-06
CY1121270T1 (el) 2020-05-29
DK3447069T3 (da) 2020-11-16
NZ708352A (en) 2019-10-25
EA031184B1 (ru) 2018-11-30
NL301173I1 (nl) 2022-05-04
PT3447069T (pt) 2020-11-13
PE20151181A1 (es) 2015-08-19
SMT201800624T1 (it) 2019-01-11
PT2922872T (pt) 2019-01-18
HUE052548T2 (hu) 2021-05-28
ES2831374T3 (es) 2021-06-08
EP3808767A1 (fr) 2021-04-21
CA2893505C (fr) 2023-02-21
AU2019200441A1 (en) 2019-02-07
HRP20182128T1 (hr) 2019-02-08
JP6773746B2 (ja) 2020-10-21
JP7019771B2 (ja) 2022-02-15
PH12015501118B1 (en) 2016-02-01
IL238796A0 (en) 2015-06-30
EP4420727A2 (fr) 2024-08-28

Similar Documents

Publication Publication Date Title
BR112014017635A2 (fr)
BR112014017614A2 (fr)
BR112014017625A2 (fr)
BR112014017659A2 (fr)
BR112014017592A2 (fr)
BR112014017607A2 (fr)
BR112014017646A2 (fr)
BR112014017638A2 (fr)
BR112013027865A2 (fr)
BR112014017609A2 (fr)
BR112014017644A2 (fr)
BR112014017634A2 (fr)
BR112014017588A2 (fr)
BR112014013184A8 (fr)
BR112014017618A2 (fr)
BR112014017647A2 (fr)
BR112014017623A2 (fr)
BR112014017652A2 (fr)
BR112014017630A2 (fr)
BR112014017627A2 (fr)
BR112014017621A2 (fr)
BR112014017631A2 (fr)
BR112014017641A2 (fr)
BR112014017622A2 (fr)
BR112014017589A2 (fr)